• Intranet
DARE-NL
  • About
    • DARE-NL
    • What are ATMPs (ENG)
    • More information
    • Wat zijn ATMPs (NL)
    • Meer weten?
  • Activities
    • Workpackage 1
    • Workpackage 2
    • Workpackage 3
    • Workpackage 4
    • Workpackage 5
    • Workpackage 6
    • Workpackage 7
  • People and Partners
    • Organisation
    • Supporting organisations
    • Management Team
    • Project Team
    • Steering Committee
    • Patient Advisory Board
    • Patient Participation Review Committee
    • Scientific Advisory Board
    • Vacancies
  • Courses & Events
    • Course directory
    • Submit new course
    • External course directories
    • Master courses
    • Upcoming events
    • Past events
    • Annual meeting
      • Annual meeting 2025
      • Annual meeting 2024
        • Program
        • Sponsors
        • Pictures
      • Annual meeting 2023
        • Program
        • Sponsors
        • Pictures
  • Resources
    • Tools
      • ATMP & Regenerative medicine
      • Regulations
      • Costs and lead times
      • Clinical trials
    • Publications
      • All publications
      • News items
      • Scientific articles
    • Newsletters
    • Links
  • Get in touch
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Behandeling van kanker in een vroeg stadium met innovatieve geneesmiddelen: wat is het ons waard? (in Dutch)

News items
https://www.dare-nl.nl/wp-content/uploads/2024/10/Interview_MSD_2.png 280 257 Susette Lauwen https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Susette Lauwen2024-10-08 12:10:482024-12-10 14:55:56Behandeling van kanker in een vroeg stadium met innovatieve geneesmiddelen: wat is het ons waard? (in Dutch)

Pictures annual DARE-NL meeting 2024

News items
https://www.dare-nl.nl/wp-content/uploads/2024/09/image00004.jpeg 1555 2400 Susette Lauwen https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Susette Lauwen2024-10-01 10:19:372024-10-21 12:16:59Pictures annual DARE-NL meeting 2024

Overzicht early access programma’s door Hollandbio (in Dutch)

News items
https://www.dare-nl.nl/wp-content/uploads/2024/10/Early-acces-Hollandbio_5.png 496 1006 Susette Lauwen https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Susette Lauwen2024-09-03 11:46:382024-11-22 13:35:46Overzicht early access programma’s door Hollandbio (in Dutch)

The Value of Gene Therapy. A study of the growth, cost and accessibility of gene therapy products (in English and Dutch)

News items
https://www.dare-nl.nl/wp-content/uploads/2024/06/Knipsel.jpg 679 543 Simone Punt https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Simone Punt2024-06-25 08:03:432024-10-21 12:50:25The Value of Gene Therapy. A study of the growth, cost and accessibility of gene therapy products (in English and Dutch)

Anke Hövels, KWF: Samen voor betere behandeling voor elke patiënt met kanker (in Dutch)

News items
https://www.dare-nl.nl/wp-content/uploads/2024/05/Knipsel-1.jpg 1017 951 Simone Punt https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Simone Punt2024-05-30 12:00:332024-10-01 10:20:19Anke Hövels, KWF: Samen voor betere behandeling voor elke patiënt met kanker (in Dutch)

NTvH interview met Dr. Trudy Straetemans over DARE-NL (in Dutch)

News items
https://www.dare-nl.nl/wp-content/uploads/2024/05/NTvH-interview.png 900 1814 Simone Punt https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Simone Punt2024-05-08 12:00:012024-09-30 13:05:58NTvH interview met Dr. Trudy Straetemans over DARE-NL (in Dutch)

Is the proposed EU General Pharmaceutical Legislation ready to support pharmaceutical innovation?

News items, Uncategorized
https://www.dare-nl.nl/wp-content/uploads/2024/07/VWS-rapport-3.jpg 766 799 Simone Punt https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Simone Punt2024-04-30 12:00:482024-08-28 12:10:29Is the proposed EU General Pharmaceutical Legislation ready to support pharmaceutical innovation?

Rapport Verkenning aanvaardbaar risico gentherapieonderzoek (in Dutch)

News items
https://www.dare-nl.nl/wp-content/uploads/2024/03/Rijksoverheid_3.png 1069 1811 Susette Lauwen https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Susette Lauwen2024-03-14 16:09:312024-05-27 07:10:10Rapport Verkenning aanvaardbaar risico gentherapieonderzoek (in Dutch)

NTvH artikel ‘DARE-NL: Nederlands platform voor snellere toegang tot ATMP’s bij kanker’ (in Dutch)

News items
https://www.dare-nl.nl/wp-content/uploads/2024/03/NTVH_3.png 1213 2400 Susette Lauwen https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Susette Lauwen2024-03-02 11:27:302024-05-27 07:33:03NTvH artikel ‘DARE-NL: Nederlands platform voor snellere toegang tot ATMP’s bij kanker’ (in Dutch)

Dashboard Doorlooptijden Geneesmiddelen opgezet door VWS (in Dutch)

News items
https://www.dare-nl.nl/wp-content/uploads/2024/02/dashboard-doorlooptijd.png 828 806 Susette Lauwen https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Susette Lauwen2024-02-02 13:19:112024-04-03 10:53:08Dashboard Doorlooptijden Geneesmiddelen opgezet door VWS (in Dutch)
Page 2 of 3123

Contact

For questions or comments related to DARE-NL or oncological ATMPs, to become a partner or connect for information

contact us at info@dare-nl.nl.

© DARE-NL

Scroll to top Scroll to top Scroll to top
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}